Impact of triple negative phenotype on prognosis and early onset of breast cancer in Iranian females

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 3, 2011, Pages 719-724

  Salami, Siamak ^a   Ramezani, Fatemeh ^a   Aghazadeh, Toofan ^a   Afshin Alavi, Hossein ^b   Ilkhanizadeh, Behrouz ^c   Maleki, Davood ^c  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b Day Hospital   (Iran)

^c URMIA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Breast cancer; Iranian females; Prognostic factors; Triple negative phenotype

Indexed keywords

EID: 79958805258     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Bray F, Moller B. (2006). Predicting the future burden of cancer. Nat Rev Cancer, 6, 63-74.
2. Bundred NJ. (2001). Prognostic and predictive factors in breast cancer. Cancer Treat Rev, 27, 137-42.
3. Cleator SJ, Palmieri C, Coombes CR. (2008). The ethnic profile of triple-negative breast cancer. Onkologie, 31, 580-2.
4. Conte P, Guarneri V. (2009) Triple-negative breast cancer: current management and future options. Ejc Supplements, 7, 14-8.
5. Dent R, Trudeau M, Pritchard KI, et al. (2007). Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res, 13, 4429-34.
6. Harirchi I, Ebrahimi M, Zamani N, et al. (2000). Breast cancer in Iran: a review of 903 case records. Public Hlth, 114, 143-5.
7. Harris L, Fritsche H, Mennel R, et al. (2007). American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin ncol, 25, 5287-312.
8. Hirabayashi YZM. (2009). Comparison of time trends in breast cancer incidence. (1973-2002) in Asia, from cancer incidence in five continents, Vols IV-IX. Japanese J Clin ncol, 39, 411-2.
9. Hung MC, Lau YK. (1999). Basic science of HER-2/neu: a review. Semin Oncol, 26, 51-9.
10. Iwase H, Kurebayashi J, Tsuda H, et al. (2010). Clinicopathological analyses of triple negative breast cancer using surveillance data from the registration committee of the Japanese breast cancer society. Breast Cancer, 17, 118-24.
11. Kolahdoozan S, Sadjadi A, Radmard AR, et al. (2010). Five common cancers in Iran. Arch Iran Med, 13, 143-6.
12. Kwon JH, Kim YJ, Lee KW, et al. (2010). Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1cm or less. BMC Cancer, 0, 557.
13. Lai HW, Kuo SJ, Chen LS, et al. (2010). Prognostic significance of triple negative breast cancer at tumor size 1cm and smaller. Eur J Surg Oncol, 37, 18-24.
14. Menashe I, Anderson WF, Jatoi I, et al. (2009). Underlying causes of the black-white racial disparity in breast cancer mortality: a population-based analysis. J Natl Cancer Inst, 01, 993-1000.
15. Mohagheghi MA, Mosavi-Jarrahi A, Malekzadeh R, et al. (2009). Cancer incidence in Tehran metropolis: the first report from the Tehran Population-based Cancer Registry, 1998-2001. Arch Iran Med, 12, 15-23.
16. Mousavi SM, Mohaghegghi MA, Mousavi-Jerrahi A, et al. (2006). Burden of breast cancer in Iran: a study of the Tehran population based cancer registry. Asian Pac J Cancer rev, 7, 571-4.
17. Mousavi SM, Mohagheghi MA, Mousavi-Jerrahi A, et al. (2008). Outcome of breast cancer in Iran: a study of Tehran cancer registry data. Asian Pac J Cancer Prev, 9, 275-8.
18. Mousavi SM, Montazeri A, Mohagheghi MA, et al. (2007). Breast cancer in Iran: an epidemiological review. Breast J, 13, 383-91.
19. Osako T, Nishimura R, Okumura Y, et al. (2008). Premenopausal status reflects an unfavorable prognosis in triple-negative breast cancer. J Clin Oncol (Meeting Abstracts), 26, 2208-.
20. Porter PL. (2009). Global trends in breast cancer incidence and mortality. Salud publica de Mexico, 51, S141-6.
21. Rakha EA, El-Sayed ME, Green AR, et al. (2007). Prognostic markers in triple-negative breast cancer. Cancer, 109, 25-32.
22. Sadjadi A, Hislop TG, Bajdik C, et al. (2009). Comparison of breast cancer survival in two populations: Ardabil, Iran and British Columbia, Canada. BMC Cancer, 9, 381.
23. Sadjadi A, Nouraie M, Mohagheghi MA, et al. (2005). Cancer occurrence in Iran in 2002, an international perspective. Asian Pac J Cancer Prev, 6, 359-63.
24. Schmitt F. (2009). HER2+ breast cancer: how to evaluate? Adv Ther, 26, S1-8.
25. Seal MD, Chia SK. (2010). What is the difference between triple-negative and basal breast cancers? Cancer J, 16, 12-6.
26. Soerjomataram I, Louwman MW, Ribot JG, et al. (2008). An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat, 107, 309-30.
27. Thorat MA, Badve S. (2007). Prognostic factors in invasive breast carcinoma: Do new molecular techniques/profiling add significantly to traditional histological factors? Current Diagnostic Pathology, 13, 116-25.
28. Trivers KF, Lund MJ, Porter PL, et al. (2009). The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control, 20, 1071-82.
29. Vahdaninia M, Montazeri A. (2004). Breast cancer in Iran: a survival analysis. Asian Pac J Cancer Prev, 5, 223-5.
30. Viale G, Bottiglieri L. (2009). Pathological definition of triple negative breast cancer. Eur J Cancer, 45, 5-10.
31. Weiss SE, Tartter PI, Ahmed S, et al. (1995). Ethnic differences in risk and prognostic factors for breast cancer. Cancer, 76, 268-74.
32. Yin WJ, Lu JS, Di GH, et al. (2009). Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients. Breast Cancer Res Treat, 115, 325-33.
33. Zhou X, Liu Q. (2010). Clinicopathological characters of triple negative breast cancer. Chinese J Cancer Res, 22, 17-20.